vs
Side-by-side financial comparison of ACADIA REALTY TRUST (AKR) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
ACADIA REALTY TRUST is the larger business by last-quarter revenue ($103.0M vs $75.5M, roughly 1.4× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -1.3%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 7.0%).
Acadia Realty Trust is a publicly traded real estate investment trust (REIT) that specializes in owning, operating, and redeveloping high-quality retail and mixed-use properties, primarily in dense, high-barrier-to-entry U.S. markets. Its portfolio includes neighborhood shopping centers, urban street retail assets, and community-focused mixed-use developments.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
AKR vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $103.0M | $75.5M |
| Net Profit | $139.1M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | 153.9% | 22.7% |
| Net Margin | 135.1% | — |
| Revenue YoY | -1.3% | 27.7% |
| Net Profit YoY | -58.2% | — |
| EPS (diluted) | — | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $103.0M | — | ||
| Q4 25 | — | $75.5M | ||
| Q3 25 | — | $54.5M | ||
| Q2 25 | — | $52.4M | ||
| Q1 25 | — | $46.0M | ||
| Q4 24 | $93.3M | $59.1M | ||
| Q3 24 | $87.7M | $80.5M | ||
| Q2 24 | $87.3M | $47.1M |
| Q1 26 | $139.1M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $8.8M | ||
| Q2 25 | — | $5.9M | ||
| Q1 25 | — | $3.0M | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $12.3M | $20.3M | ||
| Q2 24 | $1.6M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% |
| Q1 26 | 153.9% | — | ||
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | — | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | 17.5% | 22.6% | ||
| Q3 24 | 19.9% | 27.4% | ||
| Q2 24 | 20.4% | -4.6% |
| Q1 26 | 135.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 16.2% | ||
| Q2 25 | — | 11.2% | ||
| Q1 25 | — | 6.5% | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 14.0% | 25.2% | ||
| Q2 24 | 1.8% | -9.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.26 | ||
| Q3 25 | — | $0.17 | ||
| Q2 25 | — | $0.12 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | $0.08 | $0.40 | ||
| Q3 24 | $0.07 | $0.41 | ||
| Q2 24 | $0.01 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.4M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $2.6B | $130.3M |
| Total Assets | $4.5B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $31.4M | — | ||
| Q4 25 | — | $97.5M | ||
| Q3 25 | — | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | $16.8M | $101.0M | ||
| Q3 24 | $46.2M | $96.7M | ||
| Q2 24 | $31.9M | $96.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | $1.5B | $68.0M | ||
| Q3 24 | $1.6B | $79.3M | ||
| Q2 24 | $1.7B | $90.7M |
| Q1 26 | $2.6B | — | ||
| Q4 25 | — | $130.3M | ||
| Q3 25 | — | $115.3M | ||
| Q2 25 | — | $104.7M | ||
| Q1 25 | — | $97.1M | ||
| Q4 24 | $2.1B | $92.1M | ||
| Q3 24 | $1.9B | $71.1M | ||
| Q2 24 | $1.8B | $48.5M |
| Q1 26 | $4.5B | — | ||
| Q4 25 | — | $216.3M | ||
| Q3 25 | — | $202.9M | ||
| Q2 25 | — | $194.9M | ||
| Q1 25 | — | $196.2M | ||
| Q4 24 | $4.4B | $213.3M | ||
| Q3 24 | $4.3B | $220.7M | ||
| Q2 24 | $4.3B | $205.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 0.74× | 0.74× | ||
| Q3 24 | 0.82× | 1.12× | ||
| Q2 24 | 0.95× | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | 1.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | $140.4M | $15.6M | ||
| Q3 24 | $44.6M | $11.0M | ||
| Q2 24 | $32.0M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% |
| Q1 26 | 1.7% | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | 121.08× | — | ||
| Q3 24 | 3.64× | 0.54× | ||
| Q2 24 | 20.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AKR
| Rental | $98.6M | 96% |
| Other | $4.4M | 4% |
PBYI
Segment breakdown not available.
